The Food and Drug Administration has a special, streamlined process for approving generics. Trouble is, the public announcements of FDA's decisions often get...
The Food and Drug Administration has a special, streamlined process for approving generics. Trouble is, the public announcements of FDA's decisions often get bottled up. Attorney Kurt Karst, a director at Hyman, Phelps and McNamara, tells Federal Drive with Tom Temin that irritates and frustrates everyone, including drug companies, investors, federal judges and the public.
Copyright © 2024 Federal News Network. All rights reserved. This website is not intended for users located within the European Economic Area.
Tom Temin is host of the Federal Drive and has been providing insight on federal technology and management issues for more than 30 years.
Follow @tteminWFED